Literature DB >> 18397820

Synergistic anti-tumor effect of combination radio- and immunotherapy by electro-gene therapy plus intra-tumor injection of dendritic cells.

Yu-Shan Wang1, Yuk-Wah Tsang, Chau-Hua Chi, Chao-Chun Chang, Rea-Min Chu, Kwan-Hwa Chi.   

Abstract

Interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF) facilitate the maturation and functioning of injected DC. We developed a method of in situ electroporation using IL-2 and GM-CSF genes (EGT/cytokines), followed by intra-tumoral (i.t.) immature DC to determine the immune response at the tumor site using prostate-specific antigen-transfected CT26 cells. Three cycles of EGT/cytokines and i.t. DC inhibited tumor growth most effectively, but not superior to EGT/cytokines alone. However, the role of i.t. DC became significant when radiation was given after immunotherapy, which may have clinical implications on achieving better local control and prevention of systemic relapse.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397820     DOI: 10.1016/j.canlet.2008.02.063

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

Review 1.  Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities.

Authors:  Charlie Garnett-Benson; James W Hodge; Sofia R Gameiro
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

2.  Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.

Authors:  Barbara Seliger; Robert Stoehr; Diana Handke; Anja Mueller; Soldano Ferrone; Bernd Wullich; Andrea Tannapfel; Ferdinand Hofstaedter; Arndt Hartmann
Journal:  Cancer Immunol Immunother       Date:  2009-10-07       Impact factor: 6.968

3.  The effect of ionizing radiation on the homeostasis and functional integrity of murine splenic regulatory T cells.

Authors:  Andrea Balogh; Eszter Persa; Enikő Noémi Bogdándi; Anett Benedek; Hargita Hegyesi; Géza Sáfrány; Katalin Lumniczky
Journal:  Inflamm Res       Date:  2012-10-19       Impact factor: 4.575

Review 4.  Combining radiation and immunotherapy for synergistic antitumor therapy.

Authors:  Theresa A Ferrara; James W Hodge; James L Gulley
Journal:  Curr Opin Mol Ther       Date:  2009-02

5.  Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy.

Authors:  Yuk-Wah Tsang; Cheng-Chung Huang; Kai-Lin Yang; Mau-Shin Chi; Hsin-Chien Chiang; Yu-Shan Wang; Gabor Andocs; Andras Szasz; Wen-Tyng Li; Kwan-Hwa Chi
Journal:  BMC Cancer       Date:  2015-10-15       Impact factor: 4.430

Review 6.  Modulated Electrohyperthermia: A New Hope for Cancer Patients.

Authors:  Huda F Alshaibi; Bashayr Al-Shehri; Basmah Hassan; Raghad Al-Zahrani; Taghreed Assiss
Journal:  Biomed Res Int       Date:  2020-11-13       Impact factor: 3.411

7.  Recombinant heat shock protein 70 in combination with radiotherapy as a source of tumor antigens to improve dendritic cell immunotherapy.

Authors:  Yu-Shan Wang; Shih-Jen Liu; Su-Chen Huang; Chao-Chun Chang; Yi-Chun Huang; Weng-Lam Fong; Mau-Shin Chi; Kwan-Hwa Chi
Journal:  Front Oncol       Date:  2012-10-29       Impact factor: 6.244

8.  Reciprocal complementation of the tumoricidal effects of radiation and natural killer cells.

Authors:  Kai-Lin Yang; Yu-Shan Wang; Chao-Chun Chang; Su-Chen Huang; Yi-Chun Huang; Mau-Shin Chi; Kwan-Hwa Chi
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

9.  Electrotransfer of single-stranded or double-stranded DNA induces complete regression of palpable B16.F10 mouse melanomas.

Authors:  L Heller; V Todorovic; M Cemazar
Journal:  Cancer Gene Ther       Date:  2013-11-29       Impact factor: 5.987

10.  Cytosolic DNA Sensor Upregulation Accompanies DNA Electrotransfer in B16.F10 Melanoma Cells.

Authors:  Katarina Znidar; Masa Bosnjak; Maja Cemazar; Loree C Heller
Journal:  Mol Ther Nucleic Acids       Date:  2016-06-07       Impact factor: 10.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.